.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Harvard Business School
Baxter
Merck
UBS
Teva
Johnson and Johnson
Moodys
Novartis
Cantor Fitzgerald

Generated: December 12, 2017

DrugPatentWatch Database Preview

Lupin Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for LUPIN LTD, and when can generic versions of LUPIN LTD drugs launch?

LUPIN LTD has one hundred and nine approved drugs.

There is one US patent protecting LUPIN LTD drugs on LUPIN LTD drugs in the past three years. There are fifteen tentative approvals on LUPIN LTD drugs.

There are two patent family members on LUPIN LTD drugs in two countries and one hundred and eighty-nine supplementary protection certificates in thirteen countries.

Summary for Lupin Ltd

International Patents:2
US Patents:1
Tradenames:91
Ingredients:77
NDAs:109
Drug Master File Entries: 184
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Lupin LtdLEVONORGESTRELlevonorgestrelTABLET;ORAL091328-001Jan 23, 2013DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lupin LtdSUPRAXcefiximeTABLET, CHEWABLE;ORAL065380-002Oct 25, 2010RXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lupin LtdAMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDEamlodipine besylate; hydrochlorothiazide; valsartanTABLET;ORAL200797-005Jun 3, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lupin LtdMEMANTINE HYDROCHLORIDEmemantine hydrochlorideTABLET;ORAL090051-001Apr 10, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lupin LtdLAMOTRIGINElamotrigineTABLET;ORAL078691-003Jun 1, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lupin LtdFENOFIBRIC ACIDcholine fenofibrateCAPSULE, DELAYED RELEASE;ORAL200750-001Dec 4, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lupin LtdDOXYCYCLINE HYCLATEdoxycycline hyclateTABLET;ORAL208818-001Sep 27, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lupin LtdFYAVOLVethinyl estradiol; norethindrone acetateTABLET;ORAL204213-001Dec 10, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lupin LtdLOSARTAN POTASSIUMlosartan potassiumTABLET;ORAL078232-002Oct 6, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lupin LtdIMIPRAMINE PAMOATEimipramine pamoateCAPSULE;ORAL090444-002Apr 16, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for LUPIN LTD drugs

Drugname Dosage Strength Tradename Submissiondate
omeprazoleDelayed-release Tablets20 mgOMEPRAZOLE6/3/2015
cefiximefor Oral Suspension500 mg/5 mLSUPRAX7/22/2014

Non-Orange Book Patents for Lupin Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,241,905Pharmaceutical compositions of Cefixime► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Lupin Ltd Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2007119249► Subscribe
Germany112007000920► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Lupin Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
00499Netherlands► SubscribePRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114
00195Netherlands► SubscribePRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDB AAR ZUURADDITIEZOUT, IN HET BIJZONDER HET HEMISULFAAT, EN LAMIV UDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT; REGISTRTION NO/DATE: EU/04/298/001-002 20041217
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
/1997Austria► SubscribePRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
C/GB08/018United Kingdom► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
C/GB97/023United Kingdom► SubscribePRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
/2000Austria► SubscribePRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201
C/GB95/010United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
US Department of Justice
Daiichi Sankyo
Baxter
Healthtrust
AstraZeneca
Deloitte
Dow
Fish and Richardson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot